What is XLO's dilution risk score?

XLO has a latest available DilutionScore record of 37/100, categorized as medium dilution risk by the DilutionWatch scoring model. DilutionWatch displays SEC filing and dilution indicators for XLO, including shelf registrations, ATM offerings, warrant exercises, PIPE deals, and reverse split signals when detected in source data.

What SEC filings does DilutionWatch track for XLO?

DilutionWatch tracks 25 SEC filing types for XLO including S-3 shelf registrations, 424B prospectuses (ATM offerings), S-1 registration statements, 8-K material events, warrant exercise notices, convertible note agreements, and Form 4 insider transactions. Alerts are delivered via email within minutes of a filing appearing on EDGAR.

How does stock dilution affect XLO shareholders?

Stock dilution occurs when a company issues new shares, reducing the ownership percentage of existing shareholders. For XLO, common dilution events include at-the-market (ATM) stock offerings, shelf registration drawdowns, warrant exercises, and convertible note conversions. Each event increases the share count and can pressure the stock price lower.

Is DilutionWatch free for XLO tracking?

DilutionWatch provides a free tier that shows DilutionScores and basic filing history for XLO. Premium plans ($19.95/month Basic, $39.95/month Premium) unlock real-time email alerts, the full Pulse™ feed, advanced dilution forecasts, and access to all 10,000+ tracked tickers.

XLO Dilution Risk Score: 37/100 (MEDIUM)

Score Breakdown

📋 Offering Ability

46

💰 Cash Runway

0

📊 Float Risk

35

⚠️ Warrant Exposure

40

🔄 Convertible Debt

40

Dilution Forecast

☀️

Clear

No significant dilution signals

model est. 9%

💰 Capital Raise model 18%

• Active ATM program with $10M remaining capacity

🔔 Track XLO — Get forecast alerts →

Market Data

Market Cap$55.63M

Shares Outstanding5.78M

Float3.65M

Cash$136.04M

DebtN/A

Short InterestN/A

Source-Backed Evidence Depth

This public preview uses stored DilutionWatch fields and linked SEC/market records only. Missing values are not estimated.

Field	Current Value	Basis
DilutionScore	37/100	DilutionWatch score record
Shares Outstanding	5.78M	Verified float table or market cache
Public Float	3.65M	Verified float table or market cache
Market Cap	$55.63M	Market data cache
Cash Runway	56.1 months	DilutionWatch score inputs
Shelf Capacity	None in current score inputs	SEC-derived dilution fields
ATM Capacity	$9.50M	SEC-derived dilution fields
Outstanding Warrants	None in current score inputs	SEC-derived dilution fields

Recent source-backed SEC insight records available on this page: 7.

Recent SEC source mix: 4 2, 424B5 2, 8-K 1, XBRL 2.

The page does not infer future share issuance, financing probability, cash needs, management intent, or price impact when source fields are absent.

Institutional Holdings

QoQ: ↓ 93.8% shares (2026Q1 vs prior)

2 institutional holders · 2.45M shares

#1 MORGAN STANLEY 1.80M shares

#2 GILEAD SCIENCES, INC. 650.4K shares

Institutional holder totals are aggregated from ownership filings and may use a different share basis or reporting date than public float. They are not a reconciliation against tradeable float.

Short Interest

Short Interest418.3K

Days to Cover39.1

% of Float11.5%

FINRA data as of Aug 31, 2026

Insider Buy/Sell Ratio

Recent SEC Activity

xbrl XBRL WARRANT 2025-12-31

xbrl XBRL CONVERTIBLE 2021-12-31

4 INSIDER TRANSACTION 2026-03-30

4 INSIDER TRANSACTION 2026-02-17

8-K 8K EVENT 2026-02-12

Full SEC filing analysis available with free account →

Recent News

No recent news

Factual XLO Dilution Snapshot

Xilio Therapeutics, Inc. (XLO) has a DilutionScore of 37/100, rated Medium dilution risk. Score date: September 12, 2026.

Stored ATM program remaining capacity: $9.5M.
Recent SEC activity tracked for XLO: 4 on 2026-03-30; 4 on 2026-02-17; 8-K on 2026-02-12.

This automatically generated snapshot is assembled from stored DilutionWatch data fields and may contain data-source errors or omissions. It is not financial advice, not investment research, and not a recommendation. Do your own research and review the full disclaimer and terms of service.